For 1QFY2019, Aurobindo Pharma (APL) posted decent set of numbers on topline. On sales front, the company posted sales of `4,182cr v/s. `3,621cr in 1QFY2018, a yoy growth of 15.5%. On the operating front, the EBITDA margin at 17.0% v/s. 21.6% in 1QFY2018.Consequently, the Adj. PAT came in at `456cr v/s. `518cr in 1QFY2018, a yoy de-growth..